These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34248952)

  • 41. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
    Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
    Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial responses of peripheral and central nervous system glia against Staphylococcus aureus.
    Choudhury IN; Chacko A; Delbaz A; Chen M; Basu S; St John JA; Huygens F; Ekberg JAK
    Sci Rep; 2021 May; 11(1):10722. PubMed ID: 34021227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gold Nanoparticles for Imaging and Drug Transport to the CNS.
    Male D; Gromnicova R; McQuaid C
    Int Rev Neurobiol; 2016; 130():155-98. PubMed ID: 27678177
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Bonifacius A; Goldmann O; Floess S; Holtfreter S; Robert PA; Nordengrün M; Kruse F; Lochner M; Falk CS; Schmitz I; Bröker BM; Medina E; Huehn J
    Front Immunol; 2020; 11():1579. PubMed ID: 32849537
    [No Abstract]   [Full Text] [Related]  

  • 45. The barrier and interface mechanisms of the brain barrier, and brain drug delivery.
    Zhang S; Gan L; Cao F; Wang H; Gong P; Ma C; Ren L; Lin Y; Lin X
    Brain Res Bull; 2022 Nov; 190():69-83. PubMed ID: 36162603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
    Fu L; Chung R; Shi B
    Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human CD4
    Nishihara H; Soldati S; Mossu A; Rosito M; Rudolph H; Muller WA; Latorre D; Sallusto F; Sospedra M; Martin R; Ishikawa H; Tenenbaum T; Schroten H; Gosselet F; Engelhardt B
    Fluids Barriers CNS; 2020 Feb; 17(1):3. PubMed ID: 32008573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune cell entry to central nervous system--current understanding and prospective therapeutic targets.
    Prendergast CT; Anderton SM
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):315-27. PubMed ID: 20028334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The
    Gélinas M; Museau L; Milot A; Beauregard PB
    Microbiol Spectr; 2021 Dec; 9(3):e0080421. PubMed ID: 34935415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Colloidal Perspective on Targeted Drug Delivery to the Central Nervous System.
    Wang W; Hassan MM; Mao G
    Langmuir; 2023 Mar; 39(9):3235-3245. PubMed ID: 36825490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection.
    Shriver LP; Koudelka KJ; Manchester M
    J Neuroimmunol; 2009 Jun; 211(1-2):66-72. PubMed ID: 19394707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Staphylococci evade the innate immune response by disarming neutrophils and forming biofilms.
    de Vor L; Rooijakkers SHM; van Strijp JAG
    FEBS Lett; 2020 Aug; 594(16):2556-2569. PubMed ID: 32144756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virulence Factors Produced by
    Graf AC; Leonard A; Schäuble M; Rieckmann LM; Hoyer J; Maass S; Lalk M; Becher D; Pané-Farré J; Riedel K
    Mol Cell Proteomics; 2019 Jun; 18(6):1036-1053. PubMed ID: 30850421
    [No Abstract]   [Full Text] [Related]  

  • 54. CNS as an HIV-1 reservoir; BBB and drug delivery.
    Kerza-Kwiatecki AP; Amini S
    J Neurovirol; 1999 Apr; 5(2):113-4. PubMed ID: 10321974
    [No Abstract]   [Full Text] [Related]  

  • 55. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo.
    Thurlow LR; Hanke ML; Fritz T; Angle A; Aldrich A; Williams SH; Engebretsen IL; Bayles KW; Horswill AR; Kielian T
    J Immunol; 2011 Jun; 186(11):6585-96. PubMed ID: 21525381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
    Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
    Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapies for the prevention and treatment of Staphylococcus aureus infections: updates and challenges.
    Chung PY
    Pathog Dis; 2023 Jan; 81():. PubMed ID: 37422444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier.
    Tan Q; Zhao S; Xu T; Wang Q; Lan M; Yan L; Chen X
    J Mater Chem B; 2022 Nov; 10(45):9314-9333. PubMed ID: 36349976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood-brain barrier structure and function and the challenges for CNS drug delivery.
    Abbott NJ
    J Inherit Metab Dis; 2013 May; 36(3):437-49. PubMed ID: 23609350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Staphylococcal Bacterial Persister Cells, Biofilms, and Intracellular Infection Are Disrupted by JD1, a Membrane-Damaging Small Molecule.
    Dombach JL; Quintana JLJ; Detweiler CS
    mBio; 2021 Oct; 12(5):e0180121. PubMed ID: 34634935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.